Hcmed Innovations Co

Hcmed Innovations Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Hcmed Innovations Co (6934.TWO) as of Nov 6, 2026 is -27.12 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -15.23 % — a change of 78.02% (lower).

EBIT/Assets

-27.12 %

YoY

78.02%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Hcmed Innovations Co is 2025 -27.12 % . Operating Income to Assets Ratio (EBIT/Assets) of Hcmed Innovations Co was 2024 -15.23 % . It decreases by 78.02% lower compared to the previous year.

The Hcmed Innovations Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2020
-55.56 TWD
Jan 1, 2021
-45.84 TWD
Jan 1, 2022
-70.66 TWD
Jan 1, 2023
-44.08 TWD
Jan 1, 2024
-15.23 TWD
Jan 1, 2025
-27.12 TWD
The Hcmed Innovations Co EBIT/Assets history
YEAREBIT/AssetsYoY
-27.12 %+78.02%
-15.23 %-65.44%
-44.08 %-37.61%
-70.66 %+54.15%
-45.84 %-17.50%
-55.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hcmed Innovations Co Stock analysis

What does Hcmed Innovations Co do? Hcmed Innovations Co Ltd generates revenue through the design, development, production, and sales of handheld medical nebulizers tailored to pharmaceutical companies' requirements. The company offers vibrating mesh nebulizers that adjust oscillation frequency for effective drug delivery to the lower respiratory tract without specialized breathing techniques, targeting conditions like chronic obstructive pulmonary disease, asthma, cystic fibrosis, and respiratory infections. Additionally, Hcmed provides contract development and manufacturing organization (CDMO) services for drug-specific nebulizers, focusing on inhalation dosage form design and development. Key markets include the United States, Taiwan, Switzerland, Israel, and the United Kingdom, where pharmaceutical companies purchase these specialized medical devices and services. The company's primary products are vibrating mesh nebulizers and CDMO services for pharmaceutical clients. Vibrating mesh nebulizers are designed to deliver medications efficiently to the respiratory system, while CDMO services support the creation of nebulizers optimized for specific drugs. These offerings are sold to pharmaceutical companies seeking to enhance their inhalation therapy solutions. The United States, Taiwan, Switzerland, Israel, and the United Kingdom represent the main geographic segments driving sales, with pharmaceutical firms as the core customer base. Hcmed Innovations Co Ltd monetizes its expertise in medical device development by supplying both hardware and specialized manufacturing services. The vibrating mesh nebulizer technology enables precise drug delivery, addressing high-demand respiratory conditions. CDMO services further capitalize on the growing need for customized inhalation therapies, with pharmaceutical companies as the primary buyers. Sales are concentrated in the United States, Taiwan, Switzerland, Israel, and the United Kingdom, reflecting the global reach of its target market. Hcmed Innovations Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hcmed Innovations Co stock

Operating Income to Assets Ratio (EBIT/Assets) of Hcmed Innovations Co is -27.12 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Hcmed Innovations Co changed from -15.23 % to -27.12 %, representing a 78.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Hcmed Innovations Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Hcmed Innovations Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Hcmed Innovations Co

All Key Metrics — Hcmed Innovations Co